Effect of five novel 5‑substituted tetrandrine derivatives on P‑glycoprotein‑mediated inhibition and transport in Caco‑2 cells

Cao,Zhonglian; Li,Dan; Liu,Li; Yang,Ping

doi:10.3892/ol.2018.9492

Effect of five novel 5‑substituted tetrandrine derivatives on P‑glycoprotein‑mediated inhibition and transport in Caco‑2 cells

Authors:
- Zhonglian Cao
- Dan Li
- Li Liu
- Ping Yang
View Affiliations

Affiliations: Instrumental Analysis Centre, School of Pharmacy, Fudan University, Shanghai 201203, P.R. China, Department of Pharmacology, Center for Pharmacological Evaluation and Research of SIPI, Shanghai Institute of Pharmaceutical Industry, Shanghai 200437, P.R. China
Published online on: September 24, 2018 https://doi.org/10.3892/ol.2018.9492
Pages: 6808-6814

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tetrandrine (Tet) is a potent inhibitor that reverses P‑glycoprotein‑mediated multidrug resistance (MDR). A number of novel 5‑substituted tetrandrine derivatives were synthesized by the authors. The present study aimed at identifying potential P‑gp inhibitor candidates, and intracellular uptake and efflux experiments and Caco‑2 cell‑based Transwell transport studies were performed. It was demonstrated that all five test compounds were able to inhibit efflux and increase intracellular uptake of the P‑gp substrate, rhodamine‑123 (Rho‑123); the test compounds were P‑gp inhibitors. The transepithelial transport experiment indicated that the secretory (basolateral‑to‑apical) of Rho‑123 decreased, the absorption (apical‑to‑basolateral) increased and the transport efflux ratio (ER) reduced in the presence of the five compounds. Among the compounds, fluobenzene‑Tet (TF) exhibited similar inhibitory effect as Tet. Although the other four test compounds exhibited weaker inhibitory effects than Tet and TF, the compounds exhibited stronger inhibitory effects compared with the reference compound verapamil. The study demonstrated that the five novel 5‑substituted tetrandrine derivatives are able to act as inhibitors of P‑gp to overcome P‑gp‑mediated drug resistance.

View Figures

View References

1	Chen YJ: Potential role of tetrandrine in cancer therapy. Acta Pharmacol Sin. 23:1102–1106. 2002.PubMed/NCBI
2	Zhu X, Sui M and Fan W: In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res. 25:1953–1962. 2005.PubMed/NCBI
3	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
4	Tang F, Ouyang H, Yang JZ and Borchardt RT: Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers. J Pharm Sci. 93:1185–1194. 2004. View Article : Google Scholar : PubMed/NCBI
5	Oga EF, Sekine S, Shitara Y and Horie T: Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells. Am J Trop Med Hyg. 87:64–69. 2012. View Article : Google Scholar : PubMed/NCBI
6	Dong X and Mumper RJ: Nanomedicinal strategies to treat multidrug-resistant tumors: Current progress. Nanomedicine (Lond). 5:597–615. 2010. View Article : Google Scholar : PubMed/NCBI
7	Liu KJ, He JH, Su XD, Sim HM, Xie JD, Chen XG, Wang F, Liang YJ, Singh S, Sodani K, et al: Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. Int J Cancer. 132:224–235. 2013. View Article : Google Scholar : PubMed/NCBI
8	Hidalgo IJ, Raub TJ and Borchardt RT: Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 96:736–749. 1989. View Article : Google Scholar : PubMed/NCBI
9	Artursson P: Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci. 79:476–482. 1990. View Article : Google Scholar : PubMed/NCBI
10	Wacher VJ, Silverman JA, Zhang Y and Benet LZ: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 87:1322–1330. 1998. View Article : Google Scholar : PubMed/NCBI
11	Palm K, Luthman K, Ros J, Grasjo J and Artursson P: Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J Pharmacol Exp Ther. 291:435–443. 1999.PubMed/NCBI
12	Raeissi SD, Hidalgo IJ, Segura-Aguilar J and Artursson P: Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res. 16:625–632. 1999. View Article : Google Scholar : PubMed/NCBI
13	van Breemen RB and Li Y: Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol. 1:175–185. 2005. View Article : Google Scholar : PubMed/NCBI
14	Artursson P and Karlsson J: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 175:880–885. 1991. View Article : Google Scholar : PubMed/NCBI
15	Yee S: In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res. 14:763–766. 1997. View Article : Google Scholar : PubMed/NCBI
16	Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE and Grove JR: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci. 88:28–33. 1999. View Article : Google Scholar : PubMed/NCBI
17	Canitrot Y and Lautier D: Use of rhodamine 123 for the detection of multidrug resistance. Bull Cancer. 82:687–697. 1995.(In French). PubMed/NCBI
18	Ludescher C, Gattringer, Drach J, Hofmann J and Grunicke H: Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine 123. Blood. 78:1385–1387. 1991.PubMed/NCBI
19	Twentyman PR, Rhodes T and Rayner S: A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer. 30A:1–1369. 1994.PubMed/NCBI
20	Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
21	Cao Z, Li X, Liao X and Yang P: Development of an HPLC-FLD method for determination of rhodamine 123 in Caco-2 cell-based permeability studies. Chromatographia. 79:261–266. 2016. View Article : Google Scholar
22	Mi Y and Lou L: ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br J Cancer. 97:934–940. 2007. View Article : Google Scholar : PubMed/NCBI
23	Iqbal J, Hombach J, Matuszczak B and Bernkop-Schnurch A: Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J Control Release. 147:62–69. 2010. View Article : Google Scholar : PubMed/NCBI
24	Sun YF and Wink M: Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. Phytomedicine. 21:1110–1119. 2014. View Article : Google Scholar : PubMed/NCBI
25	Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5:302005. View Article : Google Scholar : PubMed/NCBI
26	Foger F, Schmitz T and Bernkop-Schnurch A: In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials. 27:4250–4255. 2006. View Article : Google Scholar : PubMed/NCBI
27	Artursson P: Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carrier Syst. 8:305–330. 1991.PubMed/NCBI
28	Rubas W, Cromwell ME, Shahrokh Z, Villagran J, Nguyen TN, Wellton M, Nguyen TH and Mrsny RJ: Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J Pharm Sci. 85:165–169. 1996. View Article : Google Scholar : PubMed/NCBI
29	Korjamo T, Honkakoski P, Toppinen MR, Niva S, Reinisalo M, Palmgrén JJ and Mönkkönen J: Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci. 26:266–279. 2005. View Article : Google Scholar : PubMed/NCBI
30	Doppenschmitt S, Spahn-Langguth H, Regardh CG and Langguth P: Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci. 88:1067–1072. 1999. View Article : Google Scholar : PubMed/NCBI
31	Tajima T, Nakajima A and Fuchigami T: Electrolytic partial fluorination of organic compounds. 83. Anodic fluorination of N-substituted pyrroles and its synthetic applications to gem-difluorinated heterocyclic compounds. J Org Chem. 71:1436–1441. 2006. View Article : Google Scholar : PubMed/NCBI